BACKGROUND: The role of transforming growth factor ␤1 (TGF-␤1) and tumor necrosis factor ␣ (TNF-␣) in asthma is unclear. The aim of this study was to assess the relationships among polymorphisms, clinical phenotypes, and the serum levels of TGF-␤1 and TNF-␣. METHODS: Polymorphisms of promoter of TGF-␤1 (C-509T locus) and TNF-␣ (G-308 A locus; rs 1800629) in 217 asthmatic patients and 110 healthy controls were evaluated. Pulmonary function, total immunoglobulin E (IgE), specific IgE antibodies, total eosinophil counts, TGF-␤1, and TNF-␣ were assessed. RESULTS: The genetic polymorphisms of TGF-␤1 promoter and TNF-␣ were significantly associated with asthma. Subjects with more severe asthma had higher serum levels of TGF-␤1 and TNF-␣. In asthmatic subjects the TGF-␤1 of atopic subjects was higher than those without atopy. All studied subjects (asthma plus control) were divided into 4 groups by mean value of TGF-␤1 or TNF-␣. The high values of TGF-␤1 or TNF-␣ were defined by higher than the mean values of the studied subjects of TGF-␤1 (392.42 pg/mL) and TNF-␣ (55.86 pg/mL). The FEV 1 of the group with high TGF-␤1 plus low TNF-␣ was lower than that in the group with low TGF-␤1 plus low TNF-␣. The lowest FEV 1 was in the group with high TNF-␣ and high TGF-␤1. CONCLUSIONS: The genetic polymorphisms of TGF-␤1 and TNF-␣ are associated with asthma. TGF-␤1 modulates atopy. Both TGF-␤1 and TNF-␣ modulate clinical severity and airway obstruction, in an additive manner.
Introduction
Asthma is a chronic inflammatory and remodeling disorder of the airways, in which many cells, cellular elements, and cytokines play important roles. Many cytokines released by T cells, innate, and structural cells contribute to the different pathogenetic features of asthma. 1, 2 The severity of asthma is difficult to assess clinically. Asthma severity has traditionally been addressed using pulmonary function data to assess the airway obstruction, but cannot reflect the underlying asthma severity in stable clinical condition. Additionally, clinical symptoms are very subjective. 3 Identifying useful biomarkers that correlate with clinical symptoms and airway obstruction would be a very important addition to clinical staging of stable asthma. Stable asthmatic patients still have chronic inflammation and remodeling in the airways, 4, 5 which induces small airway obstruction. 6 Therefore, identification of biomarkers of inflammation and remodeling in asthma may be relevant for assessment of severity of asthma.
Transforming growth factor ␤1 (TGF-␤1) is one of the main mediators involved in tissue remodeling in the asthmatic lung. This profibrotic cytokine is produced by a number of cells, including macrophages, epithelial cells, fibroblasts, and eosinophils. High expression of TGF-␤1 in patients with asthma has been reported by many investigators. However, controversy remains whether the concentration of TGF-␤1 correlates with disease severity. TGF-␤1 is believed to play an important role in most of the cellular biological processes leading to airway remodeling. It was shown to be involved in epithelial changes, subepithelial fibrosis, airway smooth muscle remodeling, and microvascular changes. 7, 8 Tumor necrosis factor ␣ (TNF-␣) has been shown to be a highly pro-inflammatory cytokine in asthma, as it upregulates adhesion molecules, increases mucin secretion, and promotes airway remodeling. TNF-␣ is produced by a large number of cells in the airways, including mast cells, smooth muscle cells, epithelial cells, monocytes, and macrophages. This cytokine has been shown to be relevant, being increased in patients with severe asthma. 9, 10 To date, association between asthma and genetic polymorphisms of TGF-␤1 or TNF-␣ remains uncertain. Furthermore, serum concentration of TGF-␤1 or TNF-␣ in asthma has not been adequately explored to assess correlations with clinical phenotypes. We studied whether the genetic polymorphisms of TGF-␤1 or TNF-␣ are associated with asthma in Taiwan. Furthermore, we investigated whether serum concentration of TGF-␤1 or TNF-␣ is associated with asthmatic severity, airway obstruction, or atopy, and whether there is additive effect on modulation of asthma by combination of both TGF-␤1 and TNF-␣.
Methods
The hospital review board for human studies approved the study protocol. Informed consent from each subject was obtained before participation. There is no conflict of interest for all authors.
Study Subjects
A cohort of 217 stable asthmatic subjects, who were diagnosed and followed up in the out-patient department of Taipei Veterans General Hospital, and 110 control subjects, who were healthy with no history of asthma or atopy, were recruited for this study (Table 1) . To be eligible for inclusion, asthmatic subjects had to be clinically stable and cooperative to follow-up in the out-patient clinic. Exclusion criteria were: severe comorbidities such as organ failure, cancer, infection, autoimmune disease, or other conditions that can affect serum TGF-␤1 and TNF-␣; and use of systemic steroids, oral anti-inflammatories, or other drugs that can affect these cytokines.
Asthmatic patients had to have all of the following characteristics, defined by the guideline of the Global Initiative for Asthma 3 : at least 2 symptoms consistent with asthma 
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(cough, wheeze and dyspnea); either a positive bronchial hyper-responsiveness or a positive bronchodilator test, defined as a Ն 15% increase in baseline FEV 1 after bronchodilator; and absence of other pulmonary disorders. Pulmonary function tests, inhaled bronchodilator response, and methacholine bronchial provocation tests were performed to confirm airway obstruction, obstruction reversibility, and airway hyper-reactivity, respectively. Pulmonary function (Automated Body Plethysmograph 6200 Autobox DL, SensorMedics, Yorba Linda, California) was assessed according to the guidelines of the American Thoracic Society. 11 Airway hyper-responsiveness was measured by bronchial challenge with methacholine. 12 Atopic phenotype was assessed based on total eosinophil count, total IgE, specific IgE, and total eosinophil count. Total IgE and specific IgE were measured from blood samples obtained from the asthmatic subjects. 12 In asthmatic subjects we assessed total IgE and IgE specific for a number of common inhaled allergens in Taiwan, namely, Dermatophagoides pteronyssinus, Dermatophagoides farinae, Dermatophagoides microceras, cockroach, cat dander, and dog dander, by immuno-enzymatic fluorescence assay (IgE-FEIA and RAST-FEIA, Pharmacia CAP, Uppsala, Sweden). The results are expressed as KU/L, according to the manufacturer's instructions. All the latter assays were performed at the same time and analyzed by the same laboratory, according to a technique previously reported in detail. 12 Total eosinophil count and IgE were measured in the enrolled asthmatic subjects.
Genotyping
DNA was extracted from blood samples with either a commercial kit (QIAamp Blood Kit, Qiagen, Chatsworth, California) or an automated nucleic acid purification system (Genepure, Applied Biosystems, Foster City, California).
Promoter of TGF-␤1 (rs 1800469)
C-509T genotyping was performed by restriction fragment length polymorphism analysis, as described in detail in the online data supplement (see the supplementary materials at http://www.rcjournal.com). An amplification of 406 bp was generated by 35 cycles of polymerase chain reaction (PCR), using sense primer 5Ј-CCGCTTCTGTC-CTTTCTAGG and antisense primer 5Ј-AAAGCGGGT-GATCCAGATG. PCR was performed in a total volume of 25 L, with 50 pmol of genomic DNA, 1U Taq polymerase (Promega, Madison, Wisconsin), 1X PCR buffer (Promega, Madison, Wisconsin), 1.5 mM Mg2 ϩ , 1 M primers, and 200 M dNTPs, with an annealing temperature of 60°C. After PCR, 10 L of the reaction mixture was digested with 1 U Eco81I (SauI) (Amersham Biosciences, Piscataway, New Jersey) in 1X buffer M (Amersham Biosciences, Piscataway, New Jersey) for 3 hours, at 37°C. The digest mixture was resolved on a 1.5% agarose gel stained with ethidium bromide. DNA from individuals with the homozygous C genotype (CC) produced 2 bands: one at 223 bp and one at 183 bp. The homozygous T genotype (TT) produced one band at 406 bp. The heterozygous genotype (CT) produced all 3 bands. 13 
Promoter of Tumor Necrosis-␣ (TNF-␣ 308 G/A, rs 1800629)
Tumor necrosis-␣ G308A polymorphism was analyzed by PCR combined with restriction fragment length polymorphism. Fragments were amplified in 15 L. The utilized primer, restriction enzyme, and expect products are as follows. The primers were 5Ј-AGG CAA TAG GTT TTG AGG GCC AT-3Ј and 5Ј-TCC TCC CTG CTC CGA TTC CG-3Ј, and the restriction enzyme was NcoI (New England BioLabs, Beverly, Massachusetts). The Ϫ308G allele yielded a single 107 bp fragment, and the Ϫ308A allele yielded 87 bp and 20 bp fragments. 14 Control DNA samples representative of each of the 3 genotypes were included on every agarose gel. Repeat genotyping was performed on 5 of every 100 samples chosen by random selection. Genotyping errors are estimated to have occurred at a frequency of Ͻ 1%. Inconsistencies were resolved by 3 or more genotyping reactions.
Blood Sampling and Analysis of Serum Content of TGF-␤1 and TNF-␣
Blood samples were taken from the antecubital vein, between 7:00 AM and 8:00 AM, after an overnight fast. Blood was processed within 1 hour of collection, and serum was aliquoted and stored at Ϫ70°C until analysis. The levels of TGF-␤1 and TNF-␣ in serum were assayed by a standardized sandwich enzyme-linked immunosorbent assay (ELISA) method (Invitrogen, Camarillo, California). The absorbance was read at 450 nm (SpectraMax M5, Molecular Devices, Sunnyvale, California).
Statistical Analysis
The values for FEV 1 %, total IgE, and total eosinophil are expressed as mean Ϯ SD. The frequency genotypes are expressed as number and percentage. A test to show whether the studied populations were in Hardy-Weinberg equilibrium was carried out. The correlation between TGF-␤1 or TNF-␣ promoter polymorphism and asthma or its phenotypes was examined by the Fisher exact test, chi-square test, or Pearson chi-square test. Analysis of variance was used to compare the values for FEV 1 %, total IgE, and total eosinophil count across the 3 genotypes or the serum level of TGF-␤1 or TNF-␣ in various severity or phenotypes of asthmatic subjects.
Results
Testing for Hardy-Weinberg Equilibrium
Our studied populations for subjects with asthma and controls showed an excellent fit to Hardy-Weinberg equilibrium.
Association Between TGF-␤1 or TNF-␣ and Asthma
The C-509T TGF-␤1 gene promoter polymorphism with C allele and TNF-␣ 238 G/A polymorphism with G allele of the asthmatic subjects were higher than the control subjects ( Table 2) .
Genotypes of the TGF-␤1 Gene Promoter or TNF-␣ in Asthmatic Subjects With Various Allergy and Non-allergy Phenotypes
We compared 2 different phenotypes in asthmatic subjects with allergy or non-allergy to mite, cockroach, dog dander, and cat dander, and found no significant differences in frequencies of TGF-␤1 or TNF-␣ gene promoters. In addition, the asthmatic subjects showed no significant difference in the frequencies of TGF-␤1 or TNF-␣ promoter gene polymorphisms with respect to normal or higher total IgE, normal or higher eosinophil counts, and normal or lower values of FEV 1 .
Serum Levels of TGF-␤1 and TNF-␣ in Different Severities of Asthma
The serum levels of TGF-␤1 and TNF-␣ were significantly different among asthma subjects with different disease severities (intermittent, mild, moderate, and severe persistent asthma). Furthermore, TNF-␣ in subjects with intermittent asthma was higher than that in normals. These results suggest that TGF-␤1 and TNF-␣ may modulate the severity of clinical phenotypes; furthermore, TNF-␣ may be more sensitive then TGF-␤1 for assessing the early stage of asthma (Fig. 1) .
TGF-␤1, TNF-␣, FEV 1 , and FVC in Normal Controls and Atopic and Non-atopic Asthmatic Subjects
The serum levels of TGF-␤1 and TNF-␣ in asthmatic subject with atopy or non-atopy was higher than those in normal controls (Table 3 ). Furthermore, the serum level of TGF-␤1 in asthmatic subjects with atopy was higher than that in asthmatic subjects with non-atopy. These results suggest that asthmatic subjects have higher TGF-␤1 and TNF-␣ in molecular phenotype, and that TGF-␤1 might modulate clinical atopic phenotype. In comparing asthmatic subjects with atopy and non-atopy, no significant difference of FEV 1 was found.
Interaction of Serum Levels of TGF-␤1 and TNF-␣
The mean values of TGF-␤1 and TNF-␣ for all study subjects, including 110 normal controls and 217 asthmatic subjects, were 392.42 pg/L and 55.86 pg/L, respectively. We defined the high or low levels based on these mean values. Four groups were assigned as follows: low TNF-␣ and low TGF-␤1; low TNF-␣ and high TGF-␤1; high TNF-␣ and low TGF-␤1; high TNF-␣ and high TGF-␤1. Values are mean Ϯ SD. * ϭ P Ͻ .05 compared with normal. † ϭ P Ͻ .05 compared with non-allergy group. ‡ ϭ P Ͻ .05 compared with allergy group of asthma. TGF-␤1 ϭ transforming growth factor ␤1 TNF-␣ ϭ tumor necrosis factor ␣ For TGF-␤1: normal vs allergy ϩ non-allergy P Ͻ .001, normal vs allergy P Ͻ .001, normal vs non-allergy P Ͻ .001, allergy vs non-allergy P ϭ .002. For TNF-␣: normal vs allergy ϩ non-allergy P ϭ .004, normal vs allergy P ϭ .001, normal vs non-allergy P ϭ .01. For FEV 1 : normal vs allergy ϩ non-allergy P Ͻ .001, normal vs allergy P Ͻ .001, normal vs non-allergy P Ͻ .001. For FVC: normal vs allergy ϩ non-allergy P Ͻ .001, normal vs allergy P Ͻ .001, normal vs non-allergy P Ͻ .001.
The FEV 1 of the low TNF-␣ and high TGF-␤1 group was lower than that of the low TNF-␣ and low TGF-␤1 group. The FEV 1 of the high TNF-␣ and high TGF-␤1 group was lower than that of the other 3 groups (Fig. 2) . These results indicate high TGF-␤1 and TNF-␣ have additive effect on reducing FEV 1 .
Discussion
Our study found polymorphisms of TGF-␤1 and TNF-␣ to be associated with asthma. The more severe clinical phenotype or airway obstruction in the asthmatic subjects was associated with higher serum TGF-␤1 or TNF-␣. Asthmatic subjects with atopy had higher TGF-␤1 levels than asthmatic subjects with non-atopy. TNF-␣ appeared to be more sensitive than TGF-␤1 for staging of early stable asthma. The combination of TGF-␤1 and TNF-␣ may have additive modulation on the degree of airway obstruction.
Results from previous studies of TGF-␤1 and TNF-␣ polymorphisms in asthma have been conflicting. Our finding showed polymorphisms of the TGF-␤1 gene promoter to be associated with asthma, as shown in a previous study. [15] [16] [17] [18] [19] [20] [21] In a subgroup analysis by ethnicity, the risk of asthma associated with the Ϫ509T allele was significantly elevated among Asians but not among whites. 21 TNF-␣ is a pro-inflammatory cytokine that is found in elevated concentrations in sputum, bronchoalveolar lavage, and lung biopsy samples from asthmatic patients. 22 It plays a central role in the initiation of airway inflammation and the generation of airway hyper-reactivity. 23 The TNF-␣ gene is a member of the TNF superfamily located on chromosome 6q21. 24 Several polymorphisms have been identified in this gene, and the -308 G/A polymorphism is one of the most studied [22] [23] [24] [25] [26] [27] [28] [29] ; however, the results were inconsistent. Our results show polymorphism in TNF-␣ gene to be associated with asthma. Our results support the recent meta-analysis showing the -308 G/A polymorphism in TNF-␣ gene to be associated with asthma risk. 30 In this meta-analysis study, subgroup analysis by ethnicity showed significant elevated risks for asthma to be associated with A allele carriers in Asians but not in whites. 30 These conflicting results may have arisen from a range of factors, such as racial/ethnic differences, linkage or case-control association study, sample size, and the strictness of the asthmatic enrolment by definite diagnosis. Asthmatic subjects in the present study were strictly enrolled based on clear diagnostic criteria, and were regularly followed up in our out-patient clinic.
Our results support a previous study showing TGF-␤1 level in asthma to be higher than normal 31, 32 ; however, the previous study demonstrated only that there was a significant difference between serum TGF-␤1 in asthmatic subjects and control subjects. 31, 32 Furthermore, our results are the first to demonstrate that the higher level of TGF-␤1 is positively correlated with severity of clinical phenotypes in asthmatic subjects. TGF-␤1 mRNA was up-regulated in bronchial tissue from subjects with severe asthma 32 and has been demonstrated to correlate with the thickness of subepithelial basement membrane. Thus, TGF-␤1 may contribute to the pathogenesis of airway remodeling in asthma. 33 Asthma is characterized by the presence of an inflammatory cell infiltrate in the bronchial mucosa, consisting of activated mast cells, eosinophils, and T cells. Several cytokines are considered to play a pivotal role in this response, particularly interleukin (IL) 4, IL-5, IL-6, and TNF-␣. Our results demonstrate for the first time the level of TNF-␣ to be significantly higher in severe clinical phenotypes of asthmatic subjects.
Asthma is a chronic inflammation and remodeling of airway disease. TNF-␣ contributes to the dysregulated inflammatory response seen in the asthmatic airway. TGF-␤1 is a main mediator involved in many aspects of persistent inflammation and tissue remodeling. Based on previous studies, both TGF-␤1 and TNF-␣ play key role in asthma pathogenesis of asthma. However, no previous research was found to investigate both cytokines' relationship in clinical phenotype and severities. We are the first to demonstrate that combined higher levels of both TGF-␤1 and TNF-␣ have additive effects on airway obstruction, as assessed by FEV 1 . Furthermore, we are first to demonstrate that serum TGF-␤1 in atopic asthmatic subjects is higher than in non-atopic asthmatic subjects. These results indicate TGF-␤1 to play an important role in atopy of clinical phenotypes in asthmatic subjects.
Limitations of this study include the small sample size, and the age of normal controls being younger than the other groups.
Conclusions
In conclusion, the polymorphisms of TGF-␤1 promoter gene and TNF-␣ gene are associated with asthma. TGF-␤1 and TNF-␣ modulate the severity of asthma, and TGF-␤1 is associated with atopy of asthmatic subjects. When combined, TGF-␤1 and TNF-␣ have additive effects on airway obstruction. Our results associating TGF-␤1 and TNF-␣ with clinical phenotypes of asthma suggest potential use of these parameters in the evaluation and management of asthma subjects, but the subject needs further investigations.
